Analysts Set LeMaitre Vascular Inc (LMAT) PT at $34.80

Share on StockTwits

Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) have been given an average recommendation of “Hold” by the nine brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $34.80.

LMAT has been the subject of several analyst reports. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a report on Monday, October 8th. ValuEngine cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, October 6th. Canaccord Genuity dropped their target price on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating for the company in a report on Monday, October 8th. Lake Street Capital cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Finally, BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, November 23rd.

In other LeMaitre Vascular news, Director Michael H. Thomas sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total transaction of $558,600.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $558,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 20.30% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bessemer Group Inc. raised its position in LeMaitre Vascular by 9.4% during the 3rd quarter. Bessemer Group Inc. now owns 21,000 shares of the medical instruments supplier’s stock valued at $814,000 after purchasing an additional 1,800 shares during the last quarter. Polen Capital Management LLC raised its position in shares of LeMaitre Vascular by 24.5% in the 2nd quarter. Polen Capital Management LLC now owns 9,849 shares of the medical instruments supplier’s stock worth $330,000 after acquiring an additional 1,941 shares in the last quarter. Strs Ohio raised its position in shares of LeMaitre Vascular by 9.5% in the 2nd quarter. Strs Ohio now owns 23,000 shares of the medical instruments supplier’s stock worth $770,000 after acquiring an additional 2,000 shares in the last quarter. Rhumbline Advisers raised its position in shares of LeMaitre Vascular by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 60,205 shares of the medical instruments supplier’s stock worth $2,016,000 after acquiring an additional 2,015 shares in the last quarter. Finally, Legal & General Group Plc raised its position in shares of LeMaitre Vascular by 7.1% in the 2nd quarter. Legal & General Group Plc now owns 30,425 shares of the medical instruments supplier’s stock worth $1,021,000 after acquiring an additional 2,018 shares in the last quarter. 81.54% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular stock traded down $0.59 during midday trading on Friday, hitting $26.01. 183,100 shares of the company’s stock were exchanged, compared to its average volume of 146,816. LeMaitre Vascular has a 52-week low of $25.63 and a 52-week high of $41.28. The stock has a market cap of $520.88 million, a price-to-earnings ratio of 30.70, a PEG ratio of 2.17 and a beta of 1.00.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, meeting the consensus estimate of $0.21. The company had revenue of $24.17 million during the quarter, compared to analysts’ expectations of $26.06 million. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. Equities research analysts predict that LeMaitre Vascular will post 1.02 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Shareholders of record on Tuesday, November 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date is Monday, November 19th. LeMaitre Vascular’s payout ratio is 32.56%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: Are analyst ratings accurate?

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liquidity Network Price Tops $0.0383 on Major Exchanges
Liquidity Network Price Tops $0.0383 on Major Exchanges
Centrica PLC  Receives Average Recommendation of “Hold” from Brokerages
Centrica PLC Receives Average Recommendation of “Hold” from Brokerages
Golos Gold  Trading 2.2% Lower  This Week
Golos Gold Trading 2.2% Lower This Week
Sienna Biopharmaceuticals  Reaches New 12-Month Low at $3.26
Sienna Biopharmaceuticals Reaches New 12-Month Low at $3.26
DavorCoin  Hits 24 Hour Volume of $0.00
DavorCoin Hits 24 Hour Volume of $0.00
Capital Product Partners  Reaches New 1-Year Low at $2.23
Capital Product Partners Reaches New 1-Year Low at $2.23


Leave a Reply

 
© 2006-2018 Zolmax.